Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Improvement of visual acuity at 6 months
研究概览
简要总结
The purpose of this study is to determine whether intravitreal injection of bevacizumab is effective in the treatment of neovascular age related macular degeneration
详细描述
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined.
The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age >50 age related macular degeneration
排除标准
- •moderate to severe cataract glaucoma intraocular surgery diabetes mellitus non controlled hypertension coronary artery disease
结局指标
主要结局
Improvement of visual acuity at 6 months
次要结局
- Leakiness in fluorangiography at 6 months
- Retinal thickness at 6 months